Related Experiment Video
Updated: May 22, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
Aurelio Maggio1, Angela Vitrano, Gaetano Lucania
1U.O.C. Ematologia II con Talassemia, Ospedali Riuniti P.O. Cervello Palermo, Palermo, Italy. aurelio.maggio@ospedaliriunitipalermo.it
Abstract:
A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1].
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Heart Failure VI: Adjunct Therapies

